Status:
COMPLETED
Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
Biogen-Dompé AG
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Protocol Title: Open-label,single center study to evaluate the savety and efficacy of an intramuscular 12 week-course of Alefacept in patients with atopic dermatitis. Study Phase: II Study Design: O...
Detailed Description
Atopic dermatitis is a common chronic eczematous skin disease,wich often begins early in infancy and runs a course of remissions and exacerbations. T-lymphocytes play a prominent role in this skin dis...
Eligibility Criteria
Inclusion
- must give written informed consent
- must be at least 18 years of age
- must have been diagnosed with atopic dermatitis fulfilling the diagnostic criteria of Hanfin und Rajka and having active inflammation
- must have a severity score of 6-9 according to Langeland and Rajka and an EASI of \> 20
- must have a PGA of "moderate","severe", or "very severe" and a pruritus score of "moderate" or"severe" at baseline
- must have total lymphocyte counts and CD4+ lymphocyte counts at or above the lower limit of normal
Exclusion
- Patients with severe diseases, that might interfere with the evaluation of AD
- Patiens with severe diseases of other organ systems that might put the patient on risk during the study or might interfere with the evaluations
- Patients older than 65 years
- Systemic treatment for atopic dermatitis ( e.g. cyclosporine, mycophenolat- mofetil,inferferon-gamma, PUVA) or systemic treatment with immunosuppressive/immunomodulating substances( e.g. azathioprin,methotrexate,biologics or hyposensitization - therapy) for other indications within 28 days prior to baseline
- local treatment for atopic dermatitis with pimecrolimus/tacrolimus, steroids \> class III, unstable use of steroid\< class III, emollients or local antiseptics/antibiotics, UVB,UVA within 14 days prior to baseline
- Serious local infection (e.g. cellulitis, abscess)or systemic infection (e.g. pneumonia,septicemia) within 3 months prior to the first dose of Alefacept
- Congenital or acquired immunodeficiency syndrome
- History of an invasive malignancy. Patients with a history of treatmend squamous cell and/or basal call carcinomas limited to the skin are not exluded
- Laboratory or clinical evidence of active tuberculosis
- Current treatment with any therapy for active tuberculosis or tuberculosis prophylaxis
- for female patients, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the investigator, during the study. the rhythm method is not to be used as the sole method of contraception. Female patients considering becoming pregnant while in the study are excluded
- female patients who are currently pregnant or breast-feeding
- abnormal chemistry, i.e., LFTs greater than three times the upper limit of normal
- Current enrollment in any other investigational drug study
- previous participation in this study or previous studies with Alefacept
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00376129
Start Date
January 1 2006
End Date
January 1 2007
Last Update
December 10 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inselspital Dermatology
Bern, Canton of Bern, Switzerland, 3110